Based on the morphological analysis, pVp-1 was classified into the family Siphoviridae and demonstrated a broad host range. This differs from a prior finding that Siphoviridae phages are generally considered to have restricted host ranges [16]. The phage infected 74% (20/27) of all multiple-antibiot- ic–resistant V. parahaemolyticus strains used in this study, in- cluding the 2 pandemic strains CRS 09-17 and CRS 09-72. Interestingly, pVp-1 infected the V. parahaemolyticus clinical isolate CRS 09-17 from a patient with diarrhea, which repre- sents a multiple-antibiotic–resistant new O3:K6 pandemic strain (tdh+, ORF8+, toxRS/new+) [4]. The results obtained from pVp-1 showed its lytic nature with a latent period and a large burst size. Full genome sequencing of pVp-1 identified no similarity match with lysogenic or phage integrase-related genes (considered as markers of temperate phages), indicating that it is a novel, newly isolated lytic phage [12]. This result emphasizes the potential of pVp-1 as a therapeutic agent, as described by Gutiérrez et al [11], who regarded lytic phages as more suitable phages for therapy. Furthermore, the stabi- lity of pVp-1 over a wide range of pH (3–11) and temperature (20°C –37°C) clearly indicates that pVp-1 would be highly sta- ble in the human body.